Therapeutic potency of mTOR signaling pharmacological inhibitors in the treatment of proinflammatory diseases, current status, and perspectives.
Arash SoltaniAmirhossein BahreyniNadia BoroumandMostafa Karimi RoshanMajid KhazeiMikhail RyzhikovSaman SoleimanpourSoodabeh ShahidsalesSeyed Mahdi HassanianPublished in: Journal of cellular physiology (2017)
Mammalian target of rapamycin (mTOR) signaling pathway controls cell energy metabolism. There is an interplay between mTOR and proinflammatory signaling pathways, supporting the role of the pathway in the pathogenesis of inflammatory diseases. Inhibition of mTOR signaling using specific pharmacological inhibitors could offer therapeutic promise in several inflammatory-associated diseases. In this review, we summarize recent findings on the regulatory effects of mTOR signaling on inflammation and the therapeutic potency of mTOR pharmacological inhibitors in the treatment of inflammatory diseases including cancer, neurodegenerative diseases, atherosclerosis, sepsis, and rheumatoid arthritis for a better understanding and hence a better management of these diseases.
Keyphrases
- cell proliferation
- signaling pathway
- oxidative stress
- rheumatoid arthritis
- current status
- pi k akt
- epithelial mesenchymal transition
- acute kidney injury
- transcription factor
- cardiovascular disease
- intensive care unit
- papillary thyroid
- squamous cell carcinoma
- induced apoptosis
- machine learning
- systemic lupus erythematosus
- disease activity
- interstitial lung disease
- replacement therapy
- smoking cessation
- lymph node metastasis
- ankylosing spondylitis
- idiopathic pulmonary fibrosis